THE BLUE BOX: A NEW AGE FOR BREAST CANCER DIAGNOSTICS

THE BLUE BOX BIOMEDICAL SOLUTIONS S.L. is a deep tech European start-up developing a medical device based on Artificial Intelligence, capable of detecting breast cancer using urine samples, with 95% accuracy.

The Blue Box presents higher performance and safety features as compared to competing technologies (mammography, MRI and gene testing): It is NON-INVASIVE unlike mammography, as it uses urine samples, NON-IRRADIATING unlike mammography that makes use of radioactive materials, USER FRIENDLY as anyone can perform the test, LOW COST (<150 €) and it can be used by several family members.

The Blue Box business plan includes two business models: one oriented to final consumers (B2C), mostly women within the US market, and the other one oriented to hospitals and health centres (B2B), oriented to the EU market.

The objective of this Women TechEU project is to assist in the scaling up of the company on the Key Partners Box of the business plan, providing support to the OUTSOURCING of 3D printing and hardware assembling experts as well as IP consultants, MARKETING to improve the awareness of the product and improve its visibility and LAUNCHING AND DISTRIBUTING THE BLUE APP associated to the device and field tested with voluntaries.

The product to be developed is a DEEP-TECH medical device based on the Internet of Things (IoT), artificial intelligence (AI) and cloud computing, making use of the latest state of the art discovery of biomarkers to detect cancer and hence fostering a new competitive, resource-efficient business model, LEAD BY JUDIT GIRÓ, THE FOUNDER AND CEO OF THE BLUE BOX.

The Blue Box has been founded in cooperation between entrepreneurs in Spain (Judit Girò), Taiwan (Po-An “Billy” Chen) and California (where the start-up is currently incubated), with a clear vision to expand the COOPERATION BETWEEN INNOVATION ECOSYSTEMS in a product by and for women: It was envisioned by a woman, founded by a woman, led by a woman and target clients are women.